A separate retrospective analysis of a larger cohort of 1091 patients with advanced NSCLC who were progression-free after at least 2 years of immune checkpoint inhibitor therapy similarly did not find ...
ACE inhibitors are well-established for limiting morbidity and mortality after MI, particularly in patients with LV dysfunction, heart failure, or both. To test the hypothesis that an angiotensin ...